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Abstract
Background Because of its low prevalence and the need for physical tests to establish a diagnosis, recruiting sarcopenic 
people for clinical studies can be a resource-intensive process.
Aims We investigated whether the  SarQoL®, a 55-item questionnaire designed to measure quality of life in sarcopenia, could 
be used to identify older people with a high likelihood of being sarcopenic, and to compare its performance to the SARC-F tool.
Methods We performed a secondary analysis of data from older, community-dwelling participants of the SarcoPhAge study, 
evaluated for sarcopenia according to the EWGSOP2 criteria, and who completed the  SarQoL® and SARC-F questionnaires. 
We determined the optimal threshold to distinguish between sarcopenic and non-sarcopenic people with the Youden index. 
Screening performance was evaluated with the area under the curve (AUC) and by calculating sensitivity and specificity.
Results The analysis of 309 participants provided an optimal threshold value of ≤ 52.4 points for identifying people with 
sarcopenia with the  SarQoL® questionnaire, which resulted in a sensitivity of 64.7% (41.1–84.2%), a specificity of 80.5% 
(75.7–84.7%) and an AUC of 0.771 (0.652–0.889). Compared to the SARC-F, the  SarQoL® has greater sensitivity (64.7% 
vs 52.39%), but slightly lower specificity (80.5% vs. 86.6%).
Discussion The  SarQoL® questionnaire showed acceptable screening accuracy, on par with the SARC-F. The optimal thresh-
old of ≤ 52.4 points should be confirmed in other cohorts of older people.
Conclusions This exploratory study showed that the  SarQoL® could potentially be applied in a screening strategy, with the 
added benefit of providing a measure of QoL at the same time.
Keywords Sarcopenia · Screening · SarQoL · Sensitivity · Specificity
Introduction
Sarcopenia has been described by the 2nd European Work-
ing Group on Sarcopenia in Older People (EWGSOP2) as a 
“progressive and generalised skeletal muscle disorder that 
is associated with increased likelihood of adverse outcomes 
including falls, fractures, physical disability and mortality”. 
In the same article, the EWGSOP2 also presented a revision 
of its diagnostic criteria for sarcopenia, presenting a new 
diagnostic algorithm and changing the threshold values for 
low muscle strength and low muscle mass [1]. This revi-
sion has increased the consistency between studies in the 
evaluation of sarcopenia, but some studies have observed 
that it lowers the prevalence of sarcopenia compared to the 
EWGSOP1 criteria [2, 3]. For clinical research and epide-
miological studies, this means that more candidates need to 
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be evaluated to achieve a sufficient number of sarcopenic 
participants to obtain the desired statistical power.
To help researchers recruit sarcopenic individuals in an 
efficient and cost-effective manner, multiple screening tools 
have been developed to identify those candidates with the 
highest probability of having sarcopenia. These come in 
different forms: there are questionnaires such as the Mini 
Sarcopenia Risk Assessment (MSRA—both a 7 and 5-item 
version available) and the SARC-F questionnaire (a 5 and 
3-item version exist, as well as a version with calf circumfer-
ence and a version which takes into account age and body 
mass) [4]. Other screening instruments rely solely on physi-
cal characteristics, such as the score developed by Ishii et al 
(age, grip strength and calf circumference), muscle mass 
prediction formulas or the chair stand test [4, 5].
Clinical studies in sarcopenia require a substantial amount 
of time and effort, because of the need to include and evalu-
ate a large number of candidates to find sufficient sarcopenic 
subjects to achieve the required level of statistical power. A 
full diagnostic evaluation where muscle mass is evaluated 
by dual-energy X-ray absorptiometry (DXA) and muscle 
strength by dynamometer, as recommended, necessitates 
the use of qualified personnel and expensive instruments. 
Given the cost per patient for these evaluations, screening 
instruments that can significantly increase the proportion of 
sarcopenic persons within the pool of candidates invited for 
a full body composition assessment could greatly help the 
financial feasibility of large-scale clinical studies in sarco-
penia. With this in mind, the hypothesis was raised that an 
existing instrument, developed to measure quality of life in 
sarcopenia, could potentially be of use in screening candi-
dates for referral to full body composition evaluation and/or 
physical function assessment.
The instrument investigated in this study is the Sarcope-
nia Quality of Life  (SarQoL®) questionnaire. It evaluates 
quality of life in sarcopenia through 55 items categorized 
into 7 domains of health-related dysfunction [6]. It is an 
auto-administered instrument and takes about 15 min to 
complete. Its clinimetric properties as a QoL questionnaire 
have been demonstrated in multiple validation studies con-
ducted in multiple languages [7–18]. Of particular interest 
in this context is the repeated observation that the  SarQoL® 
questionnaire is able to discriminate between sarcopenic and 
non-sarcopenic groups, with the former scoring significantly 
lower on the overall QoL score of the questionnaire com-
pared to the latter. Its focus on the impact of musculoskeletal 
health on quality of life contributes to our expectation that 
the overall QoL score produced by the  SarQoL® question-
naire could be used to screen older people and identify those 
with a higher likelihood of sarcopenia.
The objective of this study is therefore to evaluate the 
capacity of the Overall QoL score of the  SarQoL® ques-
tionnaire to detect individuals with sarcopenia according to 
the revised EWGSOP2 consensus criteria. The hypothesis 
linked to this objective is that the Overall QoL score of the 
 SarQoL® questionnaire has an area under the ROC curve 
(AUC) greater than 0.7, indicating the test is useful in dis-
tinguishing between sarcopenic and non-sarcopenic people 
[19].
The secondary objective of this study is to compare the 
screening performance of the Overall QoL score of the 
 SarQoL® questionnaire with the performance of the 5-item 
SARC-F questionnaire, the screening tool recommended by 
the EWGSOP2 [1]. The hypothesis linked to this objective 
is that the Overall QoL score is at least as accurate as the 
SARC-F, judged by AUC, sensitivity and specificity.
Material and methods
This study is a cross-sectional secondary evaluation of data 
collected at the third year of follow-up of the Sarcopenia 
and Physical Impairment with advancing Age (SarcoPhAge) 
prospective cohort study, carried out in the Liège province 
of Belgium [20]. The SarcoPhAge study was conducted 
in compliance with the principles outlined in the Declara-
tion of Helsinki. The study protocol and its amendments 
received approval from the Ethics Committee of the Uni-
versity Teaching Hospital of Liège (n° 2012-277), and all 
participants provided written informed consent. This article 
was written to comply, as much as feasible, with the most 
recent version of the Standards for Reporting Diagnostic 
Accuracy (STARD) checklist [21].
Participants
The SarcoPhAge study enrolled a convenience sample of 
people who visited an outpatient clinic in Liège (Belgium) 
as well as people who responded to a press advertisement 
between June 2013 and July 2014. Participants in this study 
were 65 years of age or older, and, because of the limitations 
of the dual-energy X-ray absorptiometry (DXA) instrument, 
people with a BMI above 50 kg/m2 or with amputated limbs 
were not eligible. There were no additional inclusion cri-
teria beyond these [20]. The third year of follow-up (July 
2015–2016) was selected for inclusion because this was 
the first year that both the  SarQoL® questionnaire and the 
SARC-F questionnaire were administered to all participants.
Measurements
For each participant, muscle mass was measured with a 
dual-energy X-ray absorptiometry instrument (Hologic Dis-
covery A, USA) and grip strength with the Saehan hydraulic 
hand dynamometer (Saehan Corp., Masan, South Korea). 
Both instruments were calibrated according to the respective 
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manufacturer’s instructions at the recommended intervals. 
Appendicular skeletal muscle mass was calculated as the 
sum of all 4 limbs and divided by the squared height of 
the participant in question to obtain a skeletal muscle mass 
index (SMI = ASM/Ht2). The grip strength of a person was 
defined as the highest value out of 6 measurements (3 for the 
dominant hand and 3 for the non-dominant hand). Detailed 
descriptions of both measurements are available in the arti-
cle on the baseline results of the SarcoPhAge study [20]. 
These data allowed us to diagnose sarcopenia according to 
the EWGSOP2 criteria in participants with low muscle mass 
(ASM/Ht2 < 7.0 kg/m2 for men and < 5.5 kg/m2 for women) 
and low muscle strength (grip strength < 27 kg for men 
and < 16 kg for women) [1]. Sarcopenia diagnosed with the 
EWGSOP2 criteria constitutes the reference standard in this 
study because of its status as the current consensus criteria 
and its applicability to samples recruited in Europe [1].
The index test in this study, the paper-based French-lan-
guage  SarQoL® questionnaire, was completed by the par-
ticipants without assistance. An Overall QoL score (0–100 
points) is calculated where lower scores indicate lower QoL, 
and thus also greater sarcopenia-related disability [6, 22]. 
The questionnaire is available in multiple languages from 
the website www. sarqol. org, and the Overall QoL score was 
calculated with an Access database developed for this pur-
pose. Given the exploratory nature of this investigation, we 
did not pre-specify a test-positivity cut-off point.
We included a second index test in this analysis, so as to 
be able to compare the performance of the  SarQoL® ques-
tionnaire against the current most widely used screening 
instrument in sarcopenia, the SARC-F [23]. It is composed 
of 5 questions on strength, locomotion, rising from a chair, 
climbing stairs and history of falls. A total score is calcu-
lated and ranges from 0 to 10 points, where higher scores are 
linked with a higher probability of being diagnosed with sar-
copenia. A score of ≥ 4 points is used as a cut-off to identify 
individuals who require a full examination for sarcopenia in 
clinical practice [23]. The SARC-F was developed to be able 
to detect sarcopenia as diagnosed with the EWGSOP1 cri-
teria, and a meta-analysis found a pooled sensitivity of 0.21 
(0.13–0.31) combined with a specificity of 0.90 (0.83–0.94) 
[24]. With the publication of the revised EWGSOP2 criteria, 
several authors have looked again at the performance of the 
SARC-F, and a meta-analysis that pooled the results from 
4 studies found an AUC of 0.75 (95% CI 0.71–0.78) with 
a sensitivity of 0.77 (95% CI 0.49–0.92) and a specificity 
of 0.63 (95% CI 0.43–0.79), while the same meta-analysis 
found a pooled sensitivity of 0.32 (95% CI 0.19–0.47) and 
specificity of 0.86 (95% CI 0.77–0.92) for the EWGSOP1 
criteria in 13 studies [25].
To compare the performance of the  SarQoL® ques-
tionnaire and the SARC-F instrument with a screening 
instrument based on physical indicators, we calculated the 
probability of sarcopenia according to the Ishii formula, 
which was the best-performing screening instrument in 
a comparison of 5 with the EWGSOP1 criteria [5]. For 
men, we used the formula [0.62 × (age−64) −3.09 × (grip 
strength−50) −4.64 × (calf circumference−42)] to calculate 
the sum score and the formula [1 / (1 +  e−(sum score / 10−11.9))] to 
calculate the probability of sarcopenia (expressed in percent-
age). For women, the formula [0.80 × (age−64) −5.09 × (grip 
strength−34) −3.28 × (calf circumference−42)] provided the 
sum score and the formula [1 / (1 +  e−(sum score / 10−12.5)) the 
probability of sarcopenia [26]. A sum score higher than 105 
for men and 120 for women was used as the cut-off for a high 
probability of sarcopenia [26]. To the best of our knowledge, 
its performance when used to screen patients for sarcopenia 
with the EWGSOP2 criteria has not yet been established.
The reference test and the index tests were performed by 
the same investigator or completed by the participant dur-
ing a single study visit. The study investigator also recorded 
clinical and demographic information needed for the Ishii 
formula. The results from the reference test and one of the 
index tests, the SARC-F, was directly available to the inves-
tigator. The  SarQoL® Overall score and the Ishii score, were 
calculated some time after the end of the study visit.
Statistical analyses
Statistical analyses were carried out with the Statistical 
Package for the Social Sciences version 27.0.0.0 (SPSS 
Statistics; IBM, Armonk, NY). The distribution of vari-
ables in this analysis was examined by looking at the dis-
tance between median and mean, histogram, QQ-plot, and 
the Shapiro–Wilk test. Continuous variables are presented 
as mean ± standard deviation if normally distributed and as 
median (25th–75th percentile) if not normally distributed. 
The evaluation of the screening performance of the Over-
all QoL score of the  SarQoL® questionnaire, the SARC-F 
tool and the Ishii screening test was based on their sensitiv-
ity (Se), specificity (Sp), positive likelihood ratio (LR +), 
negative likelihood ratio (LR-), positive predictive value 
(PPV), and negative predictive value (NPV) in relation to 
sarcopenia as diagnosed with the EWGSOP2 criteria. These 
values and the associated 95% confidence intervals were 
obtained through the GENLIN procedure, as outlined in 
document 422875 from IBM support [27]. Receiver Oper-
ating Characteristic (ROC) curves and the Area Under the 
Curve (AUC) provided the overall accuracy of the three 
screening instruments. An AUC value above 0.9 indicates 
high accuracy of the screening instrument, between 0.8 and 
0.9 excellent accuracy and between 0.7 and 0.8 acceptable 
accuracy [19]. The Youden J statistic (sensitivity + specific-
ity −1) was used to find the optimal cut-point for the Overall 
SarQoL score [28]. The analyses presented in this article 
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have been performed in all participants who were assessed 
for sarcopenia using the EWGSOP2 criteria, screened with 
the SARC-F questionnaire and who completed the  SarQoL® 
questionnaire at the third follow-up of the SarcoPhAge study. 
A p-value of 0.05 was considered statistically significant.
Results
A total of 309 people were included in this analysis. All par-
ticipants were assessed for sarcopenia with the EWGSOP2 
criteria in the third yearly evaluation of the SarcoPhAge 
study, and 17 (5.5%) of them were diagnosed with sarcope-
nia. The sarcopenic participants were older than those not 
diagnosed as sarcopenic [80.07 (71.98 – 86.36) years versus 
73.55 (69.68 –78.58) years, p = 0.011]. They also took more 
medication and had a lower gait speed than those not diag-
nosed with sarcopenia. The complete clinical characteristics 
for the sample are detailed in Table 1.
The SARC-F questionnaire identified 48 participants 
(15.5% of the sample) with a score ≥ 4 points and thus sus-
pected of having sarcopenia. A ROC curve of the  SarQoL® 
Overall score and the SARC-F score is presented in Fig. 1. 
The AUC for the  SarQoL® Overall score is 0.771 (95% 
CI: 0.652–0.889), and for the SARC-F 0.802 (95% CI: 
0.696–0.909).
The Youden index was maximised at ≤ 52.4 points for the 
 SarQoL® Overall score (Jc = 0.452, Se = 0.647, Sp = 0.805). 
This threshold value, together with the prespecified threshold 
for the SARC-F, were used for the construction of Table 2, 
detailing the screening accuracy of the two instruments.
The  SarQoL® Overall score, dichotomized at ≤ 52.4 
points, had, in absolute numbers, slightly greater sensi-
tivity than the SARC-F score (64.7% vs. 52.9%), because 
it correctly identified 11 out of the 17 sarcopenic partici-
pants, whereas the SARC-F correctly identified 9 out of 17. 
In terms of their specificity, the SARC-F had, in absolute 
numbers, slightly greater specificity than the  SarQoL® Over-
all score (80.5% vs. 86.6%), with 253 non-sarcopenic sub-
jects correctly identified compared to the 235 found by the 
 SarQoL® questionnaire.
Table 1  Clinical characteristics
*P-values from Mann–Whitney U-test, Pearson Chi-square or Student t-test, depending on variable charac-
teristics
Sarcopenic (n = 17) Not sarcopenic (n = 292) p-value*
Age (years) 80.07 (71.98–86.36) 73.55 (69.68–78.58) 0.011
Gender (women) 10 (58.8%) 170 (58.2%) 0.961
N° of drugs 9.00 (3.50–12.50) 6.00 (4.00–8.00) 0.035
N° of comorbidities 4.00 (3.00–7.00) 4.00 (2.00–5.00) 0.462
Gait speed (m/s) 0.70 ± 0.27 1.14 ± 0.28  < 0.001
Fig. 1  ROC curves for the  SarQoL® overall score and the SARC-F 
tool
Table 2  Screening accuracy of the  SarQoL® overall score and the 
SARC-F instrument
AUC: area under the ROC curve. Values between parentheses are the 
95% confidence interval
SarQoL SARC-F
True positives 11 9
False positives 57 39
True negatives 235 253
False negatives 6 8
Sensitivity 0.647 (0.411–0.842) 0.529 (0.301–0.750)
Specificity 0.805 (0.757–0.847) 0.866 (0.824–0.902)
Positive predictive value 0.162 (0.088–0.261) 0.188 (0.095–0.313)
Negative predictive 
value
0.975 (0.950–0.990) 0.969 (0.944–0.986)
Positive likelihood ratio 3.315 (2.175–5.051) 3.964 (2.322–6.768)
Negative likelihood ratio 0.439 (0.230–0.837) 0.543 (0.327–0.901)
AUC 0.771 (0.652–0.889) 0.802 (0.696–0.909)
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The Ishii screening test outperformed both the SARC-F 
and the  SarQoL® Overall score with an AUC of 0.884 (95% 
CI: 0.840–0.927). The Ishii screening test correctly identi-
fied all 17 sarcopenic individuals, and therefore had a sensi-
tivity of 100%, and correctly identified 224 non-sarcopenic 
individuals for a specificity of 76.7%. It flagged a total of 85 
people as being at high risk for sarcopenia, which is 27.5% 
of the total sample.
We also looked at the sensitivity and specificity of a range 
of threshold values for the  SarQoL® Overall score, which are 
displayed in Table 3.
Discussion
This exploratory study showed that the  SarQoL® question-
naire may be useful in screening potential candidates who 
are suspected of having sarcopenia for inclusion in clini-
cal trials. The AUC of 0.771 (95% CI: 0.652–0.889) places 
it into the category of screening instruments with accept-
able accuracy and confirms the primary study hypothesis. 
There might thus be a role for the  SarQoL® questionnaire 
in a recruitment strategy of a clinical trial, certainly if it 
is already being considered to measure quality of life. We 
also found that the screening accuracy of the  SarQoL® 
questionnaire in this sample was comparable to the SARC-
F questionnaire but inferior to the Ishii screening test. 
The  SarQoL® questionnaire was able to correctly identify 
more sarcopenic participants than the SARC-F (64.7% vs. 
52.9%), but at the cost of a slightly lower specificity (80.5% 
vs 86.6%). The Ishii screening test, which relies on physi-
cal parameters, correctly identified all 17 sarcopenic par-
ticipants, giving it a sensitivity of 100%, but had the lowest 
specificity of all three tests at 76.7%.
That the Ishii screening test outperforms the SARC-F and 
Overall  SarQoL® score should not be a great surprise. In 
fact, the items in the Ishii test closely resemble those that 
make up the diagnosis of sarcopenia according to the EWG-
SOP2 criteria, namely grip strength and calf circumference 
(as an indicator of muscle mass) [26]. The Ishii screening 
test has also shown, in a Polish study, that it possesses good 
screening accuracy when used to find sarcopenic people 
diagnosed with the EWGSOP2 criteria [29]. However, any 
comparison between the Ishii screening test and the SARC-
F and Overall  SarQoL® score needs to take into account 
that the Ishii screening test necessitates a face-to-face con-
tact between the researcher and the potential candidate to 
obtain grip strength and calf circumference measurements, 
whereas the SARC-F and the  SarQoL® questionnaire can 
be administered via the postal service, through the internet 
or via telephone.
The screening efficacy of the SARC-F, one of the most 
widely used tools and recommend by several organizations, 
has been investigated for multiple diagnostic criteria and 
summarized in a meta-analysis published in 2021. The 
authors found that the screening accuracy of the SARC-F 
was characterized by relatively low sensitivity (27–39%) 
combined with relatively high specificity (86–91%) when 
used in conjunction with the EWGSOP, Asian Work-
ing Group on Sarcopenia, International Working Group 
on Sarcopenia, and the Foundation for the National Insti-
tutes of Health Sarcopenia Project criteria. Interestingly, 
when they calculated the pooled sensitivity and specific-
ity of the SARC-F based on the EWGSOP2 criteria, they 
found inverse results: moderate sensitivity (77%) and lower 
specificity (63%), although these results were only based 
on 4 studies. It is also important to mention that 3 of the 
4 included studies focused on hospitalized patients, and 
that the pooled prevalence of sarcopenia was higher than 
in the general population at 21.56% [25]. We are aware of 
two other studies that are not included in this meta-analysis, 
namely Piotrowicz et al who reported a sensitivity of 35.3% 
and a specificity of 85.7%, and Nguyen et al, with a sensi-
tivity of 64.9% and a specificity of 68.2%, both of which 
recruited community-dwelling older people [29, 30]. It has 
been argued that the SARC-F is better suited to ruling out 
sarcopenia rather than case-finding, which seems to be the 
case for the last two articles mentioned, but not so for the 4 
included in the meta-analysis of Lu et al [31, 32].
In our study, the  SarQoL® questionnaire performed 
similarly to the SARC-F questionnaire, with slightly 
greater sensitivity but slightly lower specificity. The 
 SarQoL® questionnaire was able to correctly identify 
more sarcopenic patients in the sample, but the PPV of 
16.2% was lower than the PPV of 18.8% of the SARC-F 
instrument. This means that 68 people would have been 
singled out for further investigation by the  SarQoL® 
Table 3  Sensitivity and specificity for a range of threshold values for 
the  SarQoL® overall score
Se sensitivity, Sp specificity, PPV   positive predictive value, NPV 
negative predictive value
Bold value  indicates the optimal threshold identified by the Youden 
index and its associated Se, Sp, PPV and NPV
Threshold value Se Sp PPV NPV
 ≤ 30 points 5.9% 100% 100% 94.8%
 ≤ 40 points 17.6% 95.9% 20.0% 95.2%
 ≤ 50 points 52.9% 85.6% 17.6% 96.9%
 ≤ 52.4 points (opti-
mal threshold)
64.7% 80.5% 16.2% 97.5%
 ≤ 60 points 76.5% 65.8% 11.5% 98.0%
 ≤ 70 points 88.2% 40.1% 7.9% 98.3%
 ≤ 80 points 100% 21.2% 6.9% 100%
 ≤ 90 points 100% 7.9% 5.9% 100%
 ≤ 100 points 100% NA 5.5% NA
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questionnaire, and 48 for the SARC-F, for two additional 
sarcopenic subjects to be found. Therefore, in our exam-
ple, the  SarQoL® questionnaire would have been pref-
erable if the recruitment strategy called for finding the 
greatest number of sarcopenic participants in the shortest 
amount of time, accepting the extra cost in performing 
complete body composition and/or physical performance 
assessments on more people. The  SarQoL® questionnaire 
also has the advantage that it is self-administered and, 
therefore, requires fewer hours of study personnel time 
than the SARC-F, which is interviewer-administered.
The specific purpose for which a screening instru-
ment is used can influence which of its characteristics to 
prioritize. In an ideal situation, a screening instrument 
would be inexpensive, easy to administer, without side 
effects, reliable, valid, and both highly sensitive and spe-
cific. Oftentimes, however, a trade-off needs to be made 
between these characteristics. Both the SARC-F and the 
 SarQoL® questionnaire are inexpensive, easy to administer 
and without side effects given that they are questionnaires. 
The  SarQoL® questionnaire has also demonstrated to be 
reliable in multiple studies [11]. However, both the SARC-
F and the  SarQoL® questionnaire are not highly sensitive 
nor highly specific, and are not as sensitive as the Ishii 
screening test. Nonetheless, if its limitations are taken into 
account, the  SarQoL® questionnaire could be useful within 
certain contexts.
There are some limitations to take into account when 
interpreting the results of this study. First off, this study 
was a secondary analysis of data collected previously, 
and not specifically designed to answer the research ques-
tion. This has led to certain issues around the reduction 
of risk of bias, such as the fact that the research assistant 
was not blinded to the results of the body composition 
analysis, grip strength measurement and SARC-F score. 
A second issue is the fact that, because no pre-specified 
cut-off exists, we determined the optimal threshold for the 
Overall QoL score of the  SarQoL® questionnaire with the 
Youden index. This reflects the best balance between sen-
sitivity and specificity, but may not necessarily be gener-
alizable. The various studies performed with the  SarQoL® 
questionnaire have already shown that absolute quality of 
life scores can significantly differ between countries. Nor-
mative population data or pilot studies will be needed to 
inform the appropriate threshold value in different situa-
tions. Lastly, because of the design of this study, we did 
not perform sample size calculations but provided confi-
dence intervals around the main outcome values to provide 
a measure of precision. For both the  SarQoL® and the 
SARC-F questionnaire, relatively large confidence inter-
vals are observed around their point estimates, owing to 
the small number of people diagnosed with sarcopenia 
according to the EWGSOP2 criteria in this sample.
This study shows the feasibility of using the  SarQoL® 
questionnaire as a tool to select those people who may 
benefit from a complete sarcopenia evaluation. While this 
study presents an interesting new use for the  SarQoL® 
questionnaire, caution should be used in applying the 
threshold value used in this study (≤ 52.4 points) to other 
populations.
Conclusion
In the population presented in this study, the  SarQoL® 
Overall score, dichotomized at ≤ 52.4 points, performed 
roughly equal in terms of sensitivity and specificity to the 
SARC-F tool in identifying people considered sarcopenic 
with the EWGSOP2 criteria.
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